NCT01292135View on ClinicalTrials.gov

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

May 31, 2013

Conditions
B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

PCI-32765

420 mg daily

Trial Locations (6)

10065

Weill Medical College of Cornell University, New York

11042

CLL Research and Treatment Program, New Hyde Park

14642

University of Rochester, Rochester

37203

Sarah Cannon Research Institute, Nashville

77030

MD Anderson, Houston

02115

Dana Farber Cancer Center, Boston

Sponsors

Lead Sponsor

Pharmacyclics LLC.
All Listed Sponsors
lead

Pharmacyclics LLC.

INDUSTRY